Eva Medvedova

Triplet Therapy, Transplantation, and Maintenance until Progression in Myeloma

Paul G. Richardson, Susanna Jacobus, Edie Weller et al. · New England Journal of Medicine · 2022 · 463 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · Journal of Clinical Oncology · 2021 · 255 citations

Medicine, Hematology, Pharmacotherapy +17

Daratumumab plus CyBorD for patients with newly diagnosed AL amyloidosis: safety run-in results of ANDROMEDA

Giovanni Palladini, Efstathios Kastritis, Mathew S. Maurer et al. · Blood · 2020 · 208 citations · Full text

Medicine, Oncology, Pharmacotherapy +3

Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR

María‐Victoria Mateos, Pieter Sonneveld, Vânia Hungria et al. · Clinical Lymphoma Myeloma & Leukemia · 2019 · 153 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial

Luciano J. Costa, Saurabh Chhabra, Eva Medvedova et al. · The Lancet Haematology · 2023 · 150 citations · Full text

Medicine, Internal Medicine, Oncology +12